Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jvs.2020.05.015 http://scihub22266oqcxt.onion/10.1016/j.jvs.2020.05.015 32417304!7224653!32417304     free     free     free       J+Vasc+Surg 2020 ; 72 (3): 799-804 Nephropedia Template TP {{tp|p=32417304|t=2020. The need to manage the risk of thromboembolism in COVID-19 patients |pdf=|usr=}}{{32417304}} gab.com Text The need to manage the risk of thromboembolism in COVID-19 patients JO: J Vasc Surg http://www.kidney.de/pget.php?&tw=1&pmid=32417304 #FOAvip COVID-19 first appeared in Wuhan, Hubei Province, China, in December 2019. Thought to be of zoonotic origin, it has been named SARS-CoV-2 (COVID-19) and has spread rapidly. As of April 20, 2020, there have been >2.4 million cases recorded worldwide. The inflammatory process, cytokine storm, and lung injury that are associated with COVID-19 can put patients at an increased risk of thrombosis. The total incidence of thrombotic events in COVID-19 patients is currently uncertain. Those with more severe disease and with other risk factors, including increasing age, male sex, obesity, cancer, comorbidities, and intensive care unit admission, are at higher risk of these events. However, there is little international guidance on managing these risks in COVID-19 patients. In this paper, we explore the current evidence and theories surrounding thrombosis in these unique patients and reflect on experience from our center. Twit Text FOAVip The need to manage the risk of thromboembolism in COVID-19 patients ????J Vasc Surg http://www.kidney.de/pget.php?&tw=1&pmid=32417304 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32417304 #FOAvip English Wikipedia <ref>{{Cite pmid|32417304}}</ref> The need to manage the risk of thromboembolism in COVID-19 patients #MMPMID32417304 Khan IH; Savarimuthu S; Leung MST; Harky A J Vasc Surg 2020[Sep]; 72 (3): 799-804 PMID32417304show ga COVID-19 first appeared in Wuhan, Hubei Province, China, in December 2019. Thought to be of zoonotic origin, it has been named SARS-CoV-2 (COVID-19) and has spread rapidly. As of April 20, 2020, there have been >2.4 million cases recorded worldwide. The inflammatory process, cytokine storm, and lung injury that are associated with COVID-19 can put patients at an increased risk of thrombosis. The total incidence of thrombotic events in COVID-19 patients is currently uncertain. Those with more severe disease and with other risk factors, including increasing age, male sex, obesity, cancer, comorbidities, and intensive care unit admission, are at higher risk of these events. However, there is little international guidance on managing these risks in COVID-19 patients. In this paper, we explore the current evidence and theories surrounding thrombosis in these unique patients and reflect on experience from our center. |Age Factors[MESH] |Anticoagulants/*administration & dosage[MESH] |Betacoronavirus/*immunology[MESH] |Blood Coagulation/immunology[MESH] |COVID-19[MESH] |Comorbidity[MESH] |Coronavirus Infections/*complications/diagnosis/epidemiology/virology[MESH] |Cytokine Release Syndrome/*complications/immunology/virology[MESH] |Fibrin Fibrinogen Degradation Products/analysis[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/diagnosis/epidemiology/virology[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Sex Factors[MESH]The need to manage the risk of thromboembolism in COVID-19 patients (epmc).pdf DeepDyve Pubget Overpricing